Navigation Links
Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors
Date:2/21/2008

Diseases Division, where she initiated and led a number of preclinical and clinical development programs. Before GSK, Dr. Gowen was Senior Lecturer and Head, Bone Cell Biology Group, Department of Bone and Joint Medicine, University of Bath, U.K. Dr. Gowen has been honored with a number of research awards and prizes, has authored more than 125 peer-reviewed publications, reviews and book chapters, and holds five patents. She received her Ph.D. from the University of Sheffield, U.K., an M.B.A. with academic honors from The Wharton School of the University of Pennsylvania, and a B.Sc. with Honors in Biochemistry from the University of Bristol, U.K.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon for hepatitis C and LymphoStat-B (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in fall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancer. AEG40826, a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins, is expected to enter Phase 1 clinical trials for the treatment of cancer in early 2008. In addition, HGS has substantial financial rights to certain products in the GlaxoSmithKline clinical development pipeline.

For more information about HGS, please visit the Company's web site at '/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2007 Financial Results
2. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
3. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
4. Human Genome Sciences and Xencor Announce Antibody Collaboration
5. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
6. Stemagen First to Create Cloned Human Embryos From Adult Cells
7. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
8. International team identifies 480 genes that control human cell division
9. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
10. Department of Health & Human Services Names Dr. Eric Rose to National Biodefense Science Board
11. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Based on the ... surgical imaging market is dominated by four major ... imaging market. These players include GE Healthcare (U.K.), ... (Germany). , Full Report Copy at ... Healthcare can be attributed to its strong product ...
(Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytic ... next step in its expanded strategy to rebuild the ... naming of current Chief Operating Officer, Valerie Palmieri ... Chairman of the Board and CEO James LaFrance ... are effective January 1, 2015. "Jim and ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... BOSTON, Sept. 8 PAREXEL International,Corporation (Nasdaq: ... updated its forward-looking financial guidance for the,first quarter ... and for the,full Fiscal Year, in conjunction with ... and other factors discussed herein., Josef von ...
... FREMONT, Calif., Sept. 8 Vermillion, Inc.,(Nasdaq: ... a,team of scientists at Stanford University and Vermillion has ... General Meeting of the,PAD Coalition. Led by Dr. John ... Scientific Officer at Vermillion, Inc., the research team,discovered a ...
... Appointments Strengthen Executive Team, FREMONT, Calif., Sept. ... company developing a novel transdermal,delivery technology, today announced ... and CEO. The company also announced several recent,appointments ... chief,operating officer and president; John M. Vuko, executive ...
Cached Biology Technology:PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 2PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 3PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 4PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 5Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 2Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 3Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 2Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 3Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 4
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Many ancient crustaceans went extinct following a massive collapse of ... suggests modern species living in rapidly declining reef habitats may ... appear in the November issue of Geology , the ... reefs and the number of decapod crustaceans, a group that ...
... exhaust particles from traffic pollution leads to increased asthma ... this is due to increased blood levels of IL-17A, ... children with high diesel exposure. , The study by ... online in the Journal of Allergy and Clinical ...
... of the American Association of Feline Practitioners (AAFP) ... patients based on risk assessment., From ... The American Association of Feline Practitioners, (AAFP) ... updated guidelines on appropriate feline vaccination schedules based ...
Cached Biology News:Fossil record shows crustaceans vulnerable as modern coral reefs decline 2Fossil record shows crustaceans vulnerable as modern coral reefs decline 3Appropriate vaccinations schedules for feline patients outlined 2
Human Cell Line Slides...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA Detection ...
... Each Signet Level 2 Detection ... the avidin-biotin chemical bonding principle and ... to provide sensitivity, specificity and reliablility. ... immunostaining in both manual and automated ...
6X Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Biology Products: